616 related articles for article (PubMed ID: 15717745)
1. Future directions of liposome- and immunoliposome-based cancer therapeutics.
Park JW; Benz CC; Martin FJ
Semin Oncol; 2004 Dec; 31(6 Suppl 13):196-205. PubMed ID: 15717745
[TBL] [Abstract][Full Text] [Related]
2. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
3. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
4. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome.
Yang T; Choi MK; Cui FD; Kim JS; Chung SJ; Shim CK; Kim DD
J Control Release; 2007 Jul; 120(3):169-77. PubMed ID: 17586082
[TBL] [Abstract][Full Text] [Related]
6. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
Sapra P; Moase EH; Ma J; Allen TM
Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer.
Laginha KM; Moase EH; Yu N; Huang A; Allen TM
J Drug Target; 2008 Aug; 16(7):605-10. PubMed ID: 18686132
[TBL] [Abstract][Full Text] [Related]
8. Pros and cons of the liposome platform in cancer drug targeting.
Gabizon AA; Shmeeda H; Zalipsky S
J Liposome Res; 2006; 16(3):175-83. PubMed ID: 16952872
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
[TBL] [Abstract][Full Text] [Related]
10. [PEG-liposome in DDS and clinical studies].
Maruyama K
Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
[TBL] [Abstract][Full Text] [Related]
11. Liposome-based drug delivery in breast cancer treatment.
Park JW
Breast Cancer Res; 2002; 4(3):95-9. PubMed ID: 12052251
[TBL] [Abstract][Full Text] [Related]
12. From conventional to stealth liposomes: a new frontier in cancer chemotherapy.
Cattel L; Ceruti M; Dosio F
Tumori; 2003; 89(3):237-49. PubMed ID: 12908776
[TBL] [Abstract][Full Text] [Related]
13. Possibility of active targeting to tumor tissues with liposomes.
Maruyama K; Ishida O; Takizawa T; Moribe K
Adv Drug Deliv Rev; 1999 Nov; 40(1-2):89-102. PubMed ID: 10837782
[TBL] [Abstract][Full Text] [Related]
14. Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin.
Farasat A; Rahbarizadeh F; Ahmadvand D; Ranjbar S; Khoshtinat Nikkhoi S
J Liposome Res; 2019 Mar; 29(1):53-65. PubMed ID: 29621912
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
16. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
Shi C; Cao H; He W; Gao F; Liu Y; Yin L
Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
[TBL] [Abstract][Full Text] [Related]
17. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
Nam SM; Kim HS; Ahn WS; Park YS
Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027
[TBL] [Abstract][Full Text] [Related]
18. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor.
Manjappa AS; Chaudhari KR; Venkataraju MP; Dantuluri P; Nanda B; Sidda C; Sawant KK; Murthy RS
J Control Release; 2011 Feb; 150(1):2-22. PubMed ID: 21095210
[TBL] [Abstract][Full Text] [Related]
19. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
Goren D; Horowitz AT; Zalipsky S; Woodle MC; Yarden Y; Gabizon A
Br J Cancer; 1996 Dec; 74(11):1749-56. PubMed ID: 8956788
[TBL] [Abstract][Full Text] [Related]
20. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.
Noble CO; Guo Z; Hayes ME; Marks JD; Park JW; Benz CC; Kirpotin DB; Drummond DC
Cancer Chemother Pharmacol; 2009 Sep; 64(4):741-51. PubMed ID: 19184019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
